Endosense Closes an Additional USD 4.3 Million/CHF 4 Million in Series C Financing

GENEVA--(BUSINESS WIRE)--Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner. This second successful closing brings the total in series C funds raised to USD 44.6 million/CHF 41.4 million.

“The receipt of the additional series C funds represents a tremendous vote of confidence in our contact-force sensing technology and its power to transform the standard of care in the catheter ablation treatment of cardiac arrhythmias”

“The receipt of the additional series C funds represents a tremendous vote of confidence in our contact-force sensing technology and its power to transform the standard of care in the catheter ablation treatment of cardiac arrhythmias,” said Jan Keltjens, president, chief executive officer and chairman of Endosense. “The added finances will further support the development of our exciting pipeline, the roll-out of our TactiCath® Quartz contact-force sensing ablation catheter in Europe with a new direct sales force, and our program to get access to the U.S. market. All of these initiatives are solidifying our leadership position in the field.”

In November 2012, the company disclosed the successful closing of USD 40.3 million/CHF 37.4 million in series C financing, which was led by new investor NGN Capital and included large participation from all existing investors, as well as multiple employees.

About Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital. For more information, visit www.endosense.com.

Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.